Phenylbutazone: factors influencing plasma concentrations.

The author points out that whilst the total metabolic fate of phenylbutazone in man is better understood, discrepancies between single and multiple dose half-lives, as shown in the studies described, still remain to be explained. It is concluded that the mechanism responsible for limiting the plasma concentration of phenylbutazone when doses are increased requires further study.